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Interface biofunctionalization strategies try to enhance and control the interaction between implants and host
organism. Decellularized extracellular matrix (dECM) is widely used as a platform for bioengineering of medical
implants, having shown its suitability in a variety of preclinical as well as clinical models. In this study, specifically
designed, custom-made synthetic peptides were used to functionalize dECMwith different cell adhesive sequences
(RGD, REDV, and YIGSR). Effects on in vitro endothelial cell adhesion and in vivo endothelialization were
evaluated in standardized models using decellularized ovine pulmonary heart valve cusps (dPVCs) and decel-
lularized aortic grafts (dAoGs), respectively. Contact angle measurements and fluorescent labeling of custom-
made peptides showed successful functionalization of dPVCs and dAoGs. The functionalization of dPVCs with a
combination of bioactive sequences significantly increased in vitro human umbilical vein endothelial cell adhesion
compared to nonfunctionalized controls. In a functional rodent aortic transplantation model, fluorescent-labeled
peptides on dAoGs were persistent up to 10 days in vivo under exposure to systemic circulation. Although there
was a trend toward enhanced in vivo endothelialization of functionalized grafts compared to nonfunctionalized
controls, there was no statistical significance and a large biological variability in both groups. Despite failing
to show a clear biological effect in the used in vivo model system, our initial findings do suggest that en-
dothelialization onto dECM may be modulated by customized interface biofunctionalization using the presented
method. Since bioactive sequences within the dECM–synthetic peptide platform are easily interchangeable and
combinable, further control of host cell proliferation, function, and differentiation seems to be feasible, possibly
paving the way to a new generation of multifunctional dECM scaffolds for regenerative medicine.
Introduction
Native extracellular matrix (ECM) can be decel-lularized by standard detergent-based protocols under
high preservation of its ultrastructural composition and
microarchitecture1 while eliminating cell-based antigens,
such as a-Gal-epitopes or human leukocyte antigens,2 which
may trigger undesired immune response upon implantation
to a host organism.3 Therefore, decellularized ECM (dECM)
is widely used as a platform for bioengineering of medical
implants, having shown its suitability in a variety of pre-
clinical as well as clinical models.4–8
In the cardiovascular field, dECM-based approaches are
particularly pursued in heart valve and vascular graft engi-
neering.4 Here, experimental models have already success-
fully been translated into the preclinical and clinical
settings, with, for example, a first clinical series of decel-
lularized allogenic valves implanted in the pulmonary as
well as aortic positions showing promisingmid- and long-term
results.5,9 However, early graft failure due to severe calcifi-
cation, thrombogenesis, and immune response mechanisms
has also been reported in the past.10 Those adverse reactions
may have been triggered not only by remnants of immuno-
genic donor material due to incomplete decellularization11 but
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also by nonautologous ECM components lying on the free
graft surface.12 Therefore, early functional autologous
endothelialization is crucial for all ECM surfaces in direct
contact with the bloodstream. Particularly in the case of
decellularized vascular grafts (dVGs), this is of utmost
importance as insufficient or nonfunctional luminal endo-
thelialization and adverse neovessel remodeling may lead to
early and late graft failure,13 preventing dVGs from reaching
clinical suitability despite having already been successfully
tested in a multitude of experimental models.13,14
Interface biofunctionalization strategies aim to modulate
and control the interaction between implants and host or-
ganisms to enhance biocompatibility of implant materials
and potentially even regulate implant function. Surface
functionalization with ECM- or growth factor-derived
molecules is a commonly used and feasible approach to
improve host cell–scaffold interactions at the interface level
and enhance the biointegration of implant materials.15–18 In
the past, surface coating of engineered vascular grafts with
bioactive proteins, such as fibronectin, fibrin, or vascular
endothelial growth factor, has been shown to accelerate the
autologous recellularization and improve graft function.19–21
However, protein-based strategies may not lead to func-
tional endothelium or prevent neointimal hyperplasia as they
have been proven insufficient to elicit specific biological
cues required in the process of neoendothelium formation.21
In particular, a biological blood–graft interface with high
endothelial cell (EC) specificity, while suppressing activa-
tion of platelet attachment, immune cell recruitment, and
smooth muscle cell overproliferation, is crucial in the pro-
cess of in vivo endothelialization.22
In this regard, cell-specific surface functionalization can
be achieved using short synthetic peptides with defined
bioactive sequences.15,23 Interestingly, custom-made pep-
tides, which are derived from ECM proteins but encompass
only defined cell adhesive motifs, offer a series of advan-
tages compared to the use of native proteins: they are
chemically defined structures, show higher stability, and are
devoid of immunogenicity.24 Moreover, distinct bioactive
peptides can be combined to exert synergistic or comple-
mentary effects on the surface of an implant.25 Therefore, in
this study, we specifically designed and synthesized custom-
made synthetic peptides with the following cell adhesive
sequences to functionalize dECM:
 Arg-Gly-Asp (RGD)—present in fibronectin and other
proteins, critical component for mediating general cell
adhesion26,27
 Arg-Glu-Asp-Val (REDV)—adhesion ligand located in
the type III connecting segment domain of human
plasma fibronectin, targeting integrin a4b1, which is
widely expressed on ECs28,29
 Tyr-Ile-Gly-Ser-Arg (YIGSR)—a nonintegrin binding
peptide sequence present in laminin, which promotes
EC adhesion.28,30
All selected amino acid sequences are derived from
ubiquitous ECM proteins of native tissues, such as fibro-
nectin and laminin. Additionally, REDV and YIGSR spe-
cifically mediate adhesion and migration of ECs while
preventing platelet adhesion.28,31
In this proof-of-concept study, the feasibility of dECM
biofunctionalization with custom-made synthetic peptides
and biological effects of selected bioactive sequences on
in vitro EC adhesion and in vivo endothelialization were
evaluated in standardized models using decellularized ovine
pulmonary heart valve cusps (dPVCs) and decellularized
aortic grafts (dAoGs), respectively. We further hypothesized
that a combination of bioactive motifs may create higher EC
specificity than coating with single agents and, thus, may
increase the biological potential of functionalized dECM
platforms.
Materials and Methods
All animal experiments and surgical procedures were
performed in compliance with the Guide for the Care and
Use of Laboratory Animals as published by the US National
Institutes of Health (NIH Publication 85-23, revised 1996)
and approved by the local animal care committees (Regis-
tration No. A/391/2012).
Design and synthesis of custom-made
synthetic peptides
Custom-made RGD, REDV, and YIGSR cell adhesive pep-
tidesweredesigned as shown inFigure 1.The synthetic peptides
contained a spacing-anchoring moiety composed of three units
of aminohexanoic acid and one residue of mercaptopropionic
acid to ensure an appropriate orientation of the motifs and
binding within the dECM substrates.32,33 The peptides were
manually synthesized in solid phase (2-chlorotrityl chloride
resin, 200mg, 1.0 mmol/g) following the Fmoc/tBu strategy
according to a previously reported protocol.25 In brief, Fmoc-l-
amino acids were sequentially coupled at a four equivalent
excess using either OxymaPure/N,N¢-diisopropylcarbodiimide
(DIC) or HATU/N,N-diisopropylethylamine (DIEA) as cou-
pling systems.34 The efficiency of each coupling step was
monitored using the Kaiser test and/or by high-performance
liquid chromatography (HPLC) analysis. Fluorescent-labeled
peptides were obtained by acylation of the N-terminus with
5(6)-carboxyfluorescein.35 In this case, mercaptopropionic acid
was substituted by a cysteine residue incorporated at the C-
terminus of the sequence. All peptides were cleaved from the
resin with trifluoroacetic acid (TFA)–water–triisopropylsilane
(TIS) (85:10:5, v/v/v) for 1–2h in the presence of dithiothreitol
(DTT). The peptides were purified by semipreparative HPLC
and characterized by analytical HPLC using a reversed-phase
XBridge BEH130 C-18 column (4.6· 100mm, 3.5mm) (Wa-
ters, Milford, MA) and a photodiode array detector (Waters
2998), and mass spectra were recorded on a MALDI-TOF
Voyager DE RP spectrometer (Applied Biosystems, Foster
City, CA) (Table 1). All chemicals required for the synthesis,
including resins, Fmoc-l-amino acids, and coupling reagents,
were obtained from Iris Biotech GmbH (Marktredwitz, Ger-
many) and Sigma-Aldrich (St. Louis, MO).
ECM substrates and model systems
Different sources of ECM were used in this proof-of-
concept study, relying on well-characterized dECM substrates
and previously established model systems. Functionalization
capacity of dECM was first evaluated on ovine pulmonary
vascular cusps (PVCs)6 and ovine pericardium (OP),2 re-
presenting clinically relevant dECM substrates for heart valve
engineering. Fresh bovine pericardial tissue (control bovine
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pericardium [cBP]) stored in a propylalcoholic solution con-
taining EDTA was used as a control, representing an analog
to commercially available and chemically preserved ECM.36
After initially confirming the feasibility of the dECM func-
tionalization strategy, biological effects were assessed in vitro
in a standardized model system for cell adhesion onto dPVCs,
as previously described,37 and in vivo in a functional rodent
aortic graft (AoG) transplantation model, a standardized
vascular graft model system allowing the in vivo evaluation
under systemic pressure, as previously described.7
Decellularization of ECM. All ECMmaterials (except for
the chemically preserved cBP) were decellularized on a de-
tergent basis, as previously described.2,7,36 Briefly, decel-
lularization was achieved through dynamic tissue incubation
in four repetitive 12-h cycles with 0.5% sodium dodecyl
sulfate (SDS) and 0.5% deoxycholate (DCA), followed by
24 h of incubation in distilled water containing 0.05% sodium
azide and three repetitive 24-h rinsing cycles with phosphate-
buffered saline (PBS) and 1% penicillin/streptomycin. De-
cellularization quality was controlled as previously de-
scribed.38 All chemicals required were obtained from Sigma-
Aldrich and Merck (Darmstadt, Germany).
Ovine PVCs. Ovine hearts were obtained from juvenile
sheep (20–25 kg) at a local slaughterhouse and kept on ice
until further processing at our research facility. Pulmonary
heart valves were carefully dissected and decellularized in
toto. After the decellularization process, the individual pul-
monary heart valve cusps were harvested and stored in 4C
PBSwith 1%penicillin/streptomycin until further processing.
Rodent AoGs. Rodent AoGs were harvested from donor
Wistar rats (male, 200–250 g), essentially following a recent
publication, with minor modifications.7 Briefly, following
CO2 euthanization and thoracotomy, the thoracic and upper
abdominal aorta were explanted in toto and thoroughly
rinsed with heparinized PBS. A U-shaped AoG was pre-
pared by dissection of adjacent connective tissue and clip-
ping of the supra-aortal arteries. Harvested grafts were
stored in 4C PBS with 1% penicillin/streptomycin until
further processing.
FIG. 1. Custom-made synthetic
peptides. Chemical structure of
custom-made synthetic peptides
containing a spacing-anchoring
moiety composed of three units
of aminohexanoic acid and one
residue of mercaptopropionic
acid (highlighted in blue) as well
as the respective bioactive amino
acid sequence (highlighted in
green). RGD, Arg-Gly-Asp;
REDV, Arg-Glu-Asp-Val;
YIGSR, Tyr-Ile-Gly-Ser-Arg.
Color images available online at
www.liebertpub.com/tec
Table 1. Chemical Sequence and Characterization of the Peptides
Code Sequence tR (min)
a Purity (%)b Calc. m/z Exp. m/zb [M+H]+
RGD MPA-(Ahx)3-Gly-Arg-Gly-Asp-Ser-OH 4.227 97 917.46 918.29
REDV MPA-(Ahx)3-Arg-Glu-Asp-Val-OH 4.879 96 944.50 945.84
YIGSR MPA-(Ahx)3-Tyr-Ile-Gly-Ser-Arg-OH 5.503 95 1021.56 1022.94
CF-RGD CF-Arg-Gly-Asp-Ser-(Ahx)3-Cys-OH 6.421 98 1233.50 1234.84
CF-REDV CF-Arg-Glu-Asp-Val-(Ahx)3-Cys-OH 6.124 >99 1317.56 1319.72
CF-YIGSR CF-Tyr-Ile-Gly-Ser-Arg-(Ahx)3-Cys-OH 6.636 >99 1394.62 1396.79
atR and purity of the peptides were calculated by analytical high-performance liquid chromatography with a photodiode array detector.
Linear gradients, expressed as percentage of MeCN for 8min under a 1.0mL/min flow, were used as follows: RGD (10–40), REDV (10–
50), YIGSR (10–50), CF-RGD (5–50), CF-REDV (5–60), and CF-YIGSR (5–60).
bMass spectra were recorded on a MALDI-TOF (see text for details).
Ahx, aminohexanoic acid; CF, 5(6)-carboxyfluorescein; MPA, mercaptopropionic acid; tR, retention time.
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Surface functionalization of dECM
Surface functionalization of dECM was performed by
means of immersion and physical adsorption, as previously
described, for the functionalization of synthetic sur-
faces.25,39 Briefly, lyophilized bioactive peptides were re-
constituted in PBS (pH 6.5), and dECM components were
incubated for 12 h at room temperature under orbital agita-
tion at 100 rpm in varying peptide concentrations (100, 200,
and 500mM). dECM incubated in plain PBS under the same
conditions served as nonfunctionalized control. After the
incubation period, samples were gently washed with PBS
and ultrapure distilled water.
Contact angle measurement. For indirect proof of pep-
tide adhesion onto the dECM, wettability measurements were
performed before and after RGD functionalization. The ap-
parent static contact angles (CAs) were measured for the air
bubble/liquid/solid system, where the air bubble was deposited
onto the solid surface with the captive bubble technique40
(Supplementary Fig. S1; Supplementary Data are available
online at www.liebertpub.com/tec). Three microliters of bub-
bles were generated with a micrometric syringe and deposited
on the substrate surface placed upside down into a cuvette filled
with distilled Milli-Q water. The wettability studies were
performed with a CA video-based system (Contact Angle
System OCA15plus; DataPhysics, Filderstadt, Germany) and
analyzed with the SCA20 software (DataPhysics).
Fluorescent-labeled peptides. For direct proof of pep-
tide attachment to the dECM, peptide platforms were
modified to contain a fluorescent carboxyfluorescein group,
as described in the ‘‘Design and Synthesis of Custom-Made
Synthetic Peptides’’ section. The fluorescent-labeled pep-
tides were then used for dECM functionalization as de-
scribed above. Before visualization, samples were subjected
to extensive (·10) washings in ultrapure distilled water to
remove weakly adsorbed peptides off the surfaces. Labeled
peptides on dECM surface were visualized in vitro and ex
vivo by imaging with a fluorescent microscope (DM2000;
Leica, Wetzlar, Germany) and the Leica Application Suite
V3.7 software. Fluorescence intensity was measured by
image processing using built-in functions of NIH ImageJ
software.
In vitro cell adhesion studies
For in vitro cell adhesion studies on functionalized
dPVCs, primary human umbilical vein endothelial cells
(HUVECs) were used. HUVECs were cultured in a standard
cell culture incubator (Thermo Scientific, Waltham, MA) in
5% CO2 atmosphere and at 37C, maintained in endothelial
basal medium (EBM-2; PromoCell, Heidelberg, Germany)
with according supplements and 1% penicillin/streptomycin,
and passaged when 60–70% confluence was reached, while
media were exchanged every second day.
Functionalized dPVCs were surface seeded with HUVECs
(3· 105 cells/mL) in a tailor-made ECM evaluation culture
device (culture volume 300mL) to ensure standardization, as
previously described.37 After 1 and 4 h, seeded dPVCs were
washed 2· with PBS to wash off nonattached cells, stained
with 2mM calcein-AM (Invitrogen, Carlsbad, CA) for 30min
at 37C, and fixed in 2% formaldehyde for 60min. Samples
were visualized with an inverted fluorescent microscope (DM
IL LED; Leica), dividing the seeding area of each cusp into
four quadrants recorded at 5· magnification. To account for
in-sample inhomogeneity and variance, due to nonflat surface
and fluorescence dispersion, each fluorescent picture (re-
presenting one fourth of one cusp) was converted into a 16-bit
gray scale image and divided into 36 standardized rectangular
regions of interest (ROIs). For each ROI, an individual
threshold was adjusted, in order to visually distinguish the
area occupied by cells from nonseeded ECM surface. The
area occupied by cells was then measured for each ROI (total
amount of pixels) and averaged for each sample using built-in
functions of NIH ImageJ software.
In vivo endothelialization studies
For in vivo endothelialization studies, Wistar rats (male,
200–250 g) (from an in-house breed of the local animal care
facility), fed ad libitum with standard rat chow, were used as
a rodent model. Heterotopic implantation of the functiona-
lized dAoGs into the systemic circulation of recipient rats
was conducted according to a recent publication, with minor
modifications.7 Briefly, recipient rats were anesthetized with
2.0–2.5% isoflurane, orally intubated, and machine venti-
lated. After insertion of a central venous jugular vein catheter
and systemic heparanization (100 IU/kg), a median laparot-
omy was performed, and the infrarenal aorta was dissected
from the inferior vena cava. The abdominal aorta was
clamped, and the graft was anastomosed to the infrarenal aorta
in an end-to-side manner using a 10-0 monofilament nonab-
sorbable polypropylene suture (Ethicon, Norderstedt, Ger-
many). Then, the native aorta between the two anastomoses
was ligated to improve the graft perfusion, and the abdomen
was closed in layers. Graft performance was evaluated directly
after implantation and at explantation measuring peak systolic
velocity (PSVmax) at the proximal and distal graft ends with a
Philips HDX11 ultrasonography system equipped with a 15-
MHz probe (Philips, Hamburg, Germany).
Histological graft analysis. For histological graft analysis,
explanted grafts were fixed in a 4% buffered formaldehyde
solution (Carl Roth, Karlsruhe, Germany) and processed via
cryostat sectioning (CM1950; Leica) using standard proto-
cols. Frozen sections of 5mm were then stained with hema-
toxylin and eosin (HE) and Movat’s pentachrome staining
according to standard protocols and then visualized using a
transmission light microscope (DM2000; Leica).
For quantitative analysis of percentage of graft luminal
surface occupied by cells, a standardized protocol was estab-
lished: each conduit was divided into four regions as follows:
proximal anastomosis (region A1), ascending aorta (region
A2), descending aorta (region B1), and distal anastomosis with
the native recipient aorta (region B2), and representative cross
sections of each region underwent detailed histomorphological
analysis to assess the cellular content and repopulation pattern
using built-in functions of NIH ImageJ software, averaging
results of the different regions for each graft.
Immunohistological graft analysis. Cryoembedding, sec-
tioning, and fixation were performed as described above.
Afterward, cryosections were incubated sequentially for
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10min with 0.25% Triton X-100 and for 1 h with 5% bovine
serum albumin +0.1% Tween 20 at room temperature fol-
lowing incubation with primary antibodies (anti-von Will-
ebrand factor [vWF]; DAKO, Glostrup, Denmark; and
anti-alpha-smooth muscle actin [a-SMA], Sigma-Aldrich)
+1% bovine serum albumin +0.1% Tween 20 for 1 h at 37C.
Secondary antibodies were conjugated to the fluorophore
Alexa 488 (a-SMA) and Alexa 546 (vWF; Invitrogen) and
incubated (+1% bovine serum albumin +0.1% Tween 20) for
45min in a dark and humid chamber at 37C. Sections were
covered with VECTASHIELD mounting medium containing
DAPI (Vector Labs, Burlingame, CA) and visualized with a
fluorescent microscope (DM2000; Leica) and the Leica
Application Suite V3.7 software. All chemicals required
were obtained from Sigma-Aldrich and Merck.
Matrix metalloproteinase activity via in situ zymography.
To determine the matrix metalloproteinase (MMP) activity
in the explanted functionalized AoGs, in situ zymography
was performed as previously described.21 Briefly, cryosec-
tions were incubated with 10mg/mL fluorescein-labeled gel-
atin (Invitrogen) in 50mM Tris–HCl, 10mM CaCl2, 150mM
NaCl, and 5% Triton X-100 for 20 h at room temperature.
Sections were mounted with VECTASHIELD medium con-
taining DAPI, and MMP gelatinase activity was visualized by
fluorescence microscopy imaging as described above. Spe-
cificity of gelatinase activity was confirmed by incubation
with gelatin in the presence of 20mM EDTA. Comparative
quantification of the MMP activity was performed using
built-in functions of NIH ImageJ software. All chemicals
required were obtained from Sigma-Aldrich and Merck.
Statistics
Data are presented as mean– standard deviation of the
mean for all continuous variables. For direct group compar-
isons at one single time point, Student’s t-tests with or
without Welch’s correction or Mann–Whitney U tests were
performed. Statistical significance was assumed if p-values
were lower than 0.05. Data analysis was conducted with
GraphPad Prism v5.04 (GraphPad Software, San Diego, CA).
Results
Surface functionalization of dECM
Custom-made bioactive peptides containing three differ-
ent cell adhesive sequences (RGD, REDV, and YIGSR
motifs) were successfully synthesized, purified, and used for
surface functionalization of dECM tissue samples (Fig. 1).
As proof of concept, surface wettability was assessed by
means of CA measurements before and after incubation with
RGD for different dECM substrates, such as decellularized
ovine pulmonary valvular cusps (dPVCs), decellularized
ovine pericardium (dOP), and commercially available ECM
(cBP), serving as control (Fig. 2A). Apparent static CAs of
dPVCs and dOP significantly decreased after peptide incu-
bation (75.6– 6.0 vs. 51.1– 8.0 and 77.5– 2.5 vs. 50.5 –
5.9, respectively, p< 0.05), while CAs of cBP did not change
(46.0– 5.8 vs. 52.9– 4.6, p> 0.05) (Fig. 2B). The increase in
wettability, displayed by the decreasing CA values of dPVCs
and dOP after peptide incubation, indicates successful func-
tionalization of freshly decellularized ECM, while the pep-
tides seemed not efficient at functionalizing chemically
preserved ECM (cBP) under the same conditions.
To directly verify the presence of the bioactive peptides
on the dECM surface, the custom-made peptides were
modified at their N-termini with carboxyfluorescein, thereby
allowing their visualization by fluorescence microscopy. All
fluorescent-labeled peptides (CF-RGD, CF-REDV, and CF-
YIGSR) could be detected on dPVCs showing a ubiquitous
and uniform distribution on the dECM surface (Fig. 3A).
Semiquantitative analysis of absolute fluorescence intensity
revealed a concentration-dependent attachment pattern, reach-
ing saturation of labeling signal at around 200mM for all three
peptides, with a slightly higher attachment rate of the CF-
YIGSR compared to the CF-RGD and CF-REDV (Fig. 3B).
EC adhesion in vitro
Biological effect of functionalization with cell adhesive
motifs was evaluated by analyzing early EC adhesion onto
functionalized dECM in a standardized in vitro model.
Therefore, dPVCs were functionalized with either single
RDG, REDV, and YIGSR or a combination of RGD–YIGSR
or RGD–REDV at 100mM concentration and surface seeded
with HUVECs (3· 105 cells/mL) assessing the total area
occupied by cells (TAOC) after 1 and 4 h (Fig. 4A).
Functionalization with single peptides did not show a sig-
nificant difference as assessed by the TAOC compared to a
nonfunctionalized control group after 1 and 4 h (TAOC at
1 h: RGD: 17.5%– 0.3%, REDV: 19.3%– 11.5%, YIGSR:
16.1%– 7.4%, and control: 18.5%– 5.2%, and at 4 h: RGD:
29.2%– 0.4%, REDV: 26.2%– 6.0%, YIGSR: 28.4%– 5.6%,
and control: 24.3%– 6.6%) (Fig. 4B, C). Nonetheless, a trend
toward increased early EC adhesion could be observed after
4 h of incubation in the samples functionalized with the pep-
tides. This trend was clearly enhanced when dPVCs were
functionalized with peptide combinations (TAOC at 1 h:
RGD–YIGSR: 34.1%– 10.1% and RGD–REDV: 31.8%–
10.8%), reaching statistical significance at 4 h for the RGD–
REDV combination (TAOC at 4 h: RGD–YIGSR: 32.5%–
7.8% and RGD–REDV: 42.5%– 3.7%*; *p< 0.05 to control).
Endothelialization in vivo
For in vivo validation of enhanced dECM endothelialization
via biofunctionalization as observed in the previous in vitro
experiments, a chronic small animal model of infrarenal AoG
transplantation with physiological blood flow and pressure
challenge was used.7 dAoGs were functionalized with a
combination of RGD–REDV at 100mM concentration—in
analogy to the in vitro experiments, heterotopically implanted
to the systemic circulation (Fig. 5A) of recipient rats and ex-
planted at 2, 7, 10, and 14 days to evaluate the biological effect
on early endothelialization.
Operative outcome and implant function. A total of 49
rats were operated, with 27 rats receiving a functionalized
dAoG and 22 rats a nonfunctionalized dAoG, serving as a
control group. Overall mortality was 6% (n= 1 for functio-
nalized dAoG group and n= 2 for control group). Mean
operative time was 102.02 – 6.30min, and mean abdominal
aortic cross-clamp time was 51.10 – 4.44min. There were no
procedure-related differences in between groups. All recip-
ient rats reaching the explantation time point showed normal
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clinical function with adequate somatic growth and gain in
body weight and no clinical or Doppler sonographic signs of
lower body malperfusion. PSV of blood flow measured at the
proximal and distal graft sites decreased over time (proximal:
208.13– 22.42 cm/s and distal: 172.07– 18.58 cm/s at ex-
plantation), with Doppler sonographic graft patency demon-
strated at all measured time points (Fig. 5A). At explantation,
graft patency was 100% for all functionalized as well as
nonfunctionalized explanted dAoGs.
Persistence of biofunctionalization in vivo. To assess
whether functionalization of dAoGs persisted under systemic
circulation and exposure to native plasmatic enzymes in
our in vivo model system, dAoGs functionalized with
fluorescent-labeled peptides (CF-RDG/CF-REDV) were im-
planted as described above and explanted at 2 and 10 days
(n= 3, respectively). Fluorescence imaging before implanta-
tion revealed completely fluorescent dAoGs, with homoge-
neous and complete fluorescence throughout all graft layers.
FIG. 3. Biofunctionalization of dPVCs with carboxyfluorescein-labeled peptides. (A) Representative images of dPVCs
functionalized with nonlabeled REDV (control) and carboxyfluorescein-labeled CF-REDV under fluorescence imaging and
phase contrast, respectively. Carboxyfluorescein labeling, green. (B) Semiquantitative analysis of absolute fluorescence in-
tensity of dPVCs functionalized with carboxyfluorescein-labeled CF-RGD, CF-REDV, and CF-YIGSR and nonfunctionalized
controls at 100, 200, and 500mM peptide concentrations (absolute fluorescence intensity, mean–SD; *p< 0.0001). Color
images available online at www.liebertpub.com/tec
FIG. 2. Wettability of dECM before
and after RGD peptide functionaliza-
tion. (A) Representative images of the
air bubble/liquid/solid system, where
the air bubble was deposited onto the
dECM surface with the captive bubble
technique. (B) Comparison of appar-
ent CAs on respective dECM surfaces
before and after functionalization with
RGD peptide showing an increase in
wettability for freshly dECM and a
stationary wettability for chemically
preserved commercially available
dECM after functionalization (appar-
ent CA [], mean –SD; *p< 0.05).
CA, contact angle; cBP, control bo-
vine pericardium; dECM, decellular-
ized extracellular matrix; dOP,
decellularized ovine pericardium;
dPVCs, decellularized ovine pulmo-
nary heart valve cusps; SD, standard
deviation.
6 AUBIN ET AL.
Homogeneous fluorescent signal on fluorescent-labeled and
functionalized grafts was persistent after 2 and 10 days
in vivo, however, with a slight decrease in fluorescent in-
tensity (Fig. 5B).
Endothelium formation. Although histological evalua-
tion of explanted dAoGs (Fig. 6) showed cellular graft in-
filtration starting at the adventitia and sporadically reaching
the media after 48 h, semiquantitative analysis revealed no
significant formation of endothelium on dAoGs after 2 and
7 days in vivo (n= 3, respectively), neither in the functiona-
lized nor in the nonfunctionalized control group, with only
sporadic cells on the graft luminal surface (Fig. 7A). Initial
signs of relevant endothelium formation became apparent after
10 days in vivo with 4.6%– 5.7% of the luminal diameter
covered with cells in the RGD/REDV-functionalized dAoGs
as opposed to 2.6%– 3.7% in the nonfunctionalized control
group (n= 7, respectively) (Fig. 7A).
After 14 days, in vivo endothelium formation of RGD/
REDV-functionalized dAoGs already reached one fourth of
the assessed luminal graft surface, while only one fifth of the
luminal graft surface of the nonfunctionalized control group
was covered with cells (luminal diameter covered with en-
dothelium: 25.8%– 9.3% in the RGD/REDV-functionalized
group vs. 19.1% – 14.1% in the nonfunctionalized group;
n= 7, respectively). However, despite a trend toward enhanced
endothelialization in the functionalized group, this effect failed
to reach statistical significance within the limited n size of the
groups and the observed biological variability (Fig. 7A). Re-
gional graft analysis revealed endothelium formation to be
particularly enhanced by RGD/REDV functionalization in the
proximal and distal (anastomosis near) graft sites, however,
without reaching statistical significance compared to the control
group (luminal diameter covered with endothelium; region A1:
42.7%– 27.1% vs. 27.9%– 27.5%; region B1: 14.9%– 25.7%
vs. 9.5%–11.1%; RGD/REDV-functionalized group vs. non-
functionalized group, respectively) (Fig. 7B). Additionally,
there was a trend toward increased overall graft recellular-
ization in the RGD/REDV-functionalized group compared to
the nonfunctionalized control group (absolute area occupied
by cell nuclei [arbitrary units], 170.6 – 67.7 in the RGD/
REDV-functionalized group vs. 151.1 – 110.2 in the non-
functionalized group; n = 7, respectively) (Supplementary
Fig. S2).
After 14 days, in vivo signs of early intimal hyperplasia were
already apparent in the explanted grafts. A thorough analysis
of all explants was performed to assess the nature and a pos-
sible intergroup difference regarding the neointimal charac-
teristics. The ratio of multilayered hyperplastic endothelium to
single-layer endothelium was increased in the functionalized
group, with 19.7%– 22.2% versus 9.2%– 9.0% of the eval-
uated luminal graft diameter covered with hyperplastic endo-
thelium in the respective RGD/REDV-functionalized and
nonfunctionalized control groups (Fig. 7C).
Immunofluorescent staining revealed vWF-positive cells
in the newly formed endothelium in both groups, while
FIG. 4. Cellular adherence onto functionalized dPVCs. (A) Representative contrast-enhanced gray scale images of
HUVEC adherence (3 · 105 cells/mL) onto functionalized dPVCs at 1 and 4 h. As explained in the ‘‘In Vitro Cell Adhesion
Studies’’ section for semiquantitative analysis, each image was further divided into 36 ROI with individual threshold
settings accounting for in-sample inhomogeneity and variance due to nonflat surface and fluorescence dispersion. (B, C)
Semiquantitative analysis of total area occupied by cells at 1 and 4 h, respectively (%, mean – SD; *p < 0.05). HUVEC,
human umbilical vein endothelial cell; ROI, region of interest.
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medium-repopulating cells stained positive for a-SMA
(Fig. 8A, B). However, a-SMA-positive cells could also be
found in areas of multilayered hyperplastic endothelium, as
well as in seemingly single-layer endothelium. Additionally,
in situ zymography demonstrated high MMP activity, as
expected, not only around medium-repopulating cells and
hyperplastic endothelium but also within the single-layered
ECs (Fig. 8C, D and Supplementary Fig. S3). MMP activity
analyzed via semiquantitative analysis showed high in-
sample and in-group variability, with, however, consistent
high activity at an endothelial level but with no statistical
difference between groups (data not shown).
FIG. 6. In vivo endothelialization I. Representative images of HE and Movat’s pentachrome-stained explanted RGD/
REDV-functionalized and nonfunctionalized dAoGs after 2, 7, 10, and 14 days in vivo, respectively, showing the beginning
of endothelium formation starting at day 10. Additional representative higher magnitude cross section of RGD/REDV-
functionalized graft after 14 days in vivo showing endothelial layer on the luminal graft side (HE stain) and varying ECM
compositions depending on graft region (Movat’s stain). ECM, extracellular matrix; HE, hematoxylin and eosin. Color
images available online at www.liebertpub.com/tec
FIG. 5. In vivo persistence of biofunctionalization in a functional rodent aortic transplantation model. (A) Representative
macroscopic and Doppler sonographic image of an infrarenal implanted dAoG showing a functional graft. *dAoG. (B) Re-
presentative fluorescent images of a nonlabeled RGD/REDV-functionalized graft (control) showing slight autofluorescence, as
well as carboxyfluorescein-labeled CF-RGD/CF-REDV-functionalized grafts before implantation (t0) and after 2 and 10 days
in vivo showing homogeneous and complete fluorescence throughout all graft layers with a slight decrease in fluorescence
intensity over time, demonstrating in vivo persistence of biofunctionalization. dAoG, decellularized aortic graft. Color images
available online at www.liebertpub.com/tec
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Discussion
Customized biofunctionalization of decellularized ECM
Targeted functionalization of interfaces to increase bio-
compatibility is a widely explored approach in material sci-
ence.15–18 As shown in previous reports, using defined short
bioactive sequences rather than large proteins as biological
active agents, it is possible to achieve surface functionalization
with defined control of biological interaction and high cell
specificity.15,23,24 However, customized interface biofunctio-
nalization with synthetic peptides has essentially been applied
to synthetic nonbiological materials as they usually have bio-
logically inert interfaces with homogeneous surfaces allowing
controlled peptide anchoring.25,32,41,42 In the case of native-
derived ECM materials, interface modification is usually ne-
glected or gross surface coating with large unselective proteins
is performed as the interface is already constituted by bio-
logically active ECM proteins with an inhomogeneous and
anisotropic surface complicating complex functionalization
strategies.43 Therefore, in this proof-of-concept study, we
specifically designed and synthesized custom-made peptides
with interchangeable bioactive motifs containing a spacing-
anchoring moiety to ensure appropriate binding as well as
orientation of the bioactive motifs on dECM substrates. To the
best of the authors’ knowledge, this is the first study showing
customized biofunctionalization of dECM with tailor-made
synthetic peptides allowing full control of biological potential
by targeted bioactive sequence selection.
Validation of custom-made peptide binding
onto decellularized ECM
Peptide binding on dECM surfaces was confirmed and an-
alyzed by CA measurements and fluorescent microscopy. Other
techniques commonly used to characterize biomolecule binding
to synthetic surfaces, such as X-ray photoelectron spectroscopy
(XPS), quartz crystal microbalance with dissipation monitoring
(QCM-D), or optical waveguide lightmode spectroscopy
(OWLS), could not be used owing to the intricate nature of
dECM substrates.
FIG. 7. In vivo endothelialization II. Functionalization of dAoGs implanted in functional aortic transplantation model shows
a trend toward enhanced in vivo endothelialization and hyperplastic endothelium formation. (A) Semiquantitative analysis of
luminal graft diameter covered by cells of explanted RGD/REDV-functionalized and nonfunctionalized (control) dAoGs after
2, 7, 10, and 14 days in vivo (%, mean – SD). (B) Semiquantitative analysis of regional luminal graft diameter covered by cells
of explanted RGD/REDV-functionalized and nonfunctionalized dAoGs after 14 days in vivo. A1, proximal anastomosis; B2,
distal anastomosis (%, mean – SD). (C) Relative ratio of multilayered hyperplastic endothelium to single-layer endothelium in
explanted RGD/REDV-functionalized and nonfunctionalized dAoGs after 14 days in vivo (%, mean–SD).
FIG. 8. In vivo endothelialization
III. (A, B) Representative immuno-
fluorescent images of explanted RGD/
REDV-functionalized dAoGs after
14 days in vivo showing vWF-positive
cells on the inner luminal graft surface
and a-SMA-positive cells in the media
region. Blue, DAPI; red, vWF; green,
a-SMA. (C, D) Representative images
of in situ zymography of explanted
RGD/REDV-functionalized dAoGs
after 14 days in vivo showing MMP
activity not only around medium-
repopulating cells and hyperplastic
endothelium but also within the
single-layered ECs. Blue, DAPI;
green, MMP-active regions. a-SMA,
alpha-smooth muscle actin; ECs, en-
dothelial cells; MMP, matrix metallo-
proteinase; vWF, von Willebrand
factor. Color images available online
at www.liebertpub.com/tec
CUSTOMIZED BIOFUNCTIONALIZATION OF DECELLULARIZED ECM 9
CA measurements allow the detection of minor changes in
the surface composition or morphology40,44 and thus are fre-
quently used to monitor protein adsorption and the functio-
nalization of diverse substrates. To fully preserve the integrity
of dECM samples, dPVCs were immersed in distilled water,
and CA was measured using the captive bubble technique.
This approach proved useful to analyze the wettability of this
type of substrate. In particular, wettability of dPVCs and dOPs
significantly increased after RGD functionalization despite the
heterogeneity and roughness of dECM samples, suggesting the
efficiency of the biofunctionalization process. This finding is
consistent with the presence of polar guanidine and carboxyl
groups present in the sequence of the bioactive RGD bio-
molecule. In contrary, apparent CA measurements in cBP,
already indicating a different wettability compared to dECM,
did not change before and after peptide functionalization, in-
dicating a lower efficiency of the functionalization process as
expected due to the chemical preservation of the commercially
available ECM by incubation in an alcohol solution.
Fluorescent labeling of the peptides via incorporation of
5(6)-carboxyfluorescein into the peptide sequence and fluo-
rescent analysis of the functionalized dECMsubstrates directly
confirmed CAmeasurements and allow quantifying the extent
of peptide binding. Interestingly, fluorescence imaging re-
vealed the fluorescent-labeled peptides to be present
throughout all dAoG vascular graft layers, exceeding simple
surface coating. This may be explained by the small molecular
size and the porosity of the dECM,45 leading to peptide dif-
fusion throughout the ECM scaffold. Additionally, the hy-
drophobic aminohexanoic acid residues present in the
synthetic peptides might also contribute to improve the re-
tention of the peptide via hydrophobic interactions with the
substrates. As previously reported, dECM scaffolds are rich in
collagenous proteins,1,2,8 which contain a high abundance of
hydrophobic amino acids (i.e., alanine, glycine, and proline),
and could therefore favor these interactions. According to the
scale of hydrophilicity described by Hopp and Woods,46 val-
ues of hydrophilicity for RGD, REDV, and YIGSR peptides
are 6.3, 7.5, and -0.8, respectively, indicating a strong hy-
drophobic character for YIGSR. This is concordant to our
observation that this peptide most efficiently immobilized on
the dPVCs compared to the other sequences.
Furthermore, custom-made peptides could be detected
within dAoG vascular grafts up to 10 days under systemic
circulation and despite exposure to native plasmatic en-
zymes in our in vivo model system, ensuring peptide pres-
ence at the beginning of the in vivo endothelialization
process. This observation is highly relevant because it
demonstrates that our functionalization strategy does pro-
vide a stable binding of the peptides to the dECM substrate
even under in vivo conditions.
Evaluation of biological effects of functionalization
of decellularized ECM via custom-made
synthetic peptides
The observed binding of custom-made synthetic peptides
onto dECM translated into a measurable biological response
in vitro, demonstrating the feasibility of customized dECM
biofunctionalization. Particularly, dual functionalization by
combining peptides containing the Arg-Gly-Asp (RGD)
sequence with those containing either the Arg-Glu-Asp-Val
(REDV) sequence or the Tyr-Ile-Gly-Ser-Arg (YIGSR) se-
quence increased EC adhesion in vitro compared to mono-
or nonfunctionalized controls. The best combination was the
equimolar mixture of RGD with REDV, which yielded
statistically higher values of EC adhesion after 4 h of in-
cubation in comparison to control. The capacity of the
REDV sequence to mediate EC adhesion through integrin
a4b1 supports the observed synergistic biological effect.46,47
Those findings were concordant to previous reports, dem-
onstrating that specificity of functionalization can be aug-
mented by targeted bioactive sequence selection and
combinatory application thereof.15,22,25,39,48
Validation in a functional rodent aortic transplantation
model under physiological flow conditions and full exposure
to the native blood7 failed to show a significant biologi-
cal effect despite showing in vivo persistence of the dECM
functionalization. Although a trend toward increased in vivo
endothelialization of the functionalized dAoGs compared to
the nonfunctionalized controls could be observed, it failed to
reach statistical significance within the number of animals
subjected to our model system and due to observed large
biological variability of the early endothelialization process,
which was also evident in the control group.
Additional findings of this study although still cir-
cumstantiate the biological effects of RDG/REDV functio-
nalization, there was a trend of increased overall graft
recellularization—coherent with the peptide presence
throughout all graft layers—and enhancement of neointimal
hyperplasia in the functionalized dAoGs. This is consistent
with previous in vivo findings, in which adventitial bioactive
coating of dAoGs stimulated repopulation of the media re-
gion21 and luminal fibronectin or RGD coating triggered
neointima formation.21,49 Nonetheless, further studies are
warranted, evaluating the possible effects of customized
biofunctionalization of dECM on in vivo endothelialization.
Biological potential of custom-made synthetic peptides
for the functionalization of decellularized ECM
Biological potential of ECM-derived protein coating of
dECM has already been demonstrated in the past, with, for
example, fibronectin coating accelerating autologous graft
recellularization.21 However, protein-based coatings may
prove insufficient to selectively elicit specific biological cues
potentially required in the process of neoendothelium for-
mation, thus failing in providing functional endothelium.21
This is concordant with the intrinsic limitations associated
with the use of full-length proteins as coating molecules,
which include low specificity, limited stability, and immu-
nogenicity.24 Thus, newer strategies aiming at circumventing
the limitations of classical protein-based methods are war-
ranted in the design of functional biological grafts.
This study demonstrates that a high degree of customi-
zation in dECM functionalization can be achieved by the
presented approach, whereas the combination of targeted
peptide motifs may simplify the complexity of natural ECM
proteins while improving the biological activity of single
peptides, for example, increasing the specificity of substrate
functionalization. Advanced multiactive peptide platforms
based on the design presented in this study and with the
capacity to simultaneously present two distinct bioactive
peptide motifs in a chemically defined manner have already
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been successfully synthesized and used on non-ECM ma-
terials.25 As demonstrated in this study, dECM functiona-
lization via synthetic peptides is feasible, so that using those
advanced platforms further controls selective bioactive se-
quence presentation, as well as combinations from a wide
range of biologically relevant peptide motifs will become
available. Therefore, simultaneous and directed activation of
relevant synergistic domains, control of selective cell ad-
hesion, specific regulation of cell differentiation and pro-
liferation, and activation of antifouling and/or antibacterial
properties on dECM may become possible.
Implications for cardiovascular bioengineering
For cardiovascular applications, interface characteristics
are highly important as cardiovascular implants usually lie
in direct contact to the bloodstream with adverse biological
effects, such as thrombosis, intimal hyperplasia, and calci-
fication leading to possible fatal consequences.50 Therefore,
early functional endothelialization is crucial for all non-
autologous surfaces in direct contact with the bloodstream.
Here, interface functionalization approaches—enhancing
in vivo autologous recellularization—may omit tedious cell-
and bioreactor-based ex vivo preimplant procedures8,51–53 as
they may not only enhance EC adhesion to ligands of the
basal membrane but also stabilize the neoendothelium in
front of shear forces generated by the bloodstream.53
Nonetheless, current approaches, although enhancing
in vivo endothelialization, have failed to prevent and even
may lead to increased neointima formation.21,49 This is
particularly important as, for example, in the case of en-
gineered vascular grafts, adverse neovessel remodeling di-
rectly leads to early and late graft failure.13 Here, the
integration of antiproliferative motifs preventing smooth
muscle cell overproliferation 42 into a customized functio-
nalization approach may pave the way to a new generation
of multifunctional dECM scaffolds.
Hence, customized biofunctionalization of dECM with
high cell specificity and selectivity in the provoked biological
response may have great implications for cardiovascular
bioengineering. As a whole concert of biological effects takes
place during in vivo graft remodeling, directed multilevel
control of dECM–blood interfaces may greatly improve car-
diovascular implants. Our findings suggest that through the
presented dECM biofunctionalization strategy—with an ad-
equate selection and combination of bioactive motifs and
advanced peptide platforms—targeted EC specificity of
dECM without activation of platelet attachment, immune cell
recruitment, and smooth muscle cell overproliferation could
possibly be achieved. Furthermore, as shown in this study,
custom-made synthetic peptides may also be used to func-
tionalize nonluminal parts of dECM as—due to their small
molecular size—they seem to diffuse into the porous ECM.
This may open up possibilities to influence graft remodeling
through directed cell migration and activation throughout
dECM-based grafts, having a great impact especially for the
engineering of vascular grafts and heart valves.
Limitations
This study was intended as a proof-of-concept study on the
feasibility of customized dECM functionalization via tailor-
made synthetic peptides. Although customized functionali-
zation of dECM with selected bioactive peptides adhering to
dECM surfaces in vitro and up to 10 days in a physiologically
functional in vivo model could be shown for the first time,
biological response in the used in vivomodel was not as clear
as expected, failing to reach statistical significance within the
used setting. The reasons may lie not only in the high bio-
logical variance of the short observation period compared to
similar studies, where the same model was used for consid-
erably longer periods,21 but also in the selection of bioactive
sequences, which may not be the ideal ones when looking at
early re-endothelialization in this particular small animal
model. Therefore, further studies identifying target bioactive
motifs, which will help selectively recruit ECs and prevent
neointima formation, are warranted as they could easily be
integrated in the presented approach and may lead the way
toward enhanced endothelialization.
Conclusions
In this proof-of-concept study, dECM was successfully
functionalized with custom-made synthetic peptides showing
increased EC attachment on functionalized dPVCs in vitro and
functionalization persistence under systemic pressure condi-
tions as well as a trend toward enhanced endothelialization of
functionalized dAoGs in vivo, which, however, failed to reach
statistical significance in the usedmodel system. To the best of
the authors’ knowledge, this is the first study showing cus-
tomized biofunctionalization of dECMwith targeted bioactive
sequences. Furthermore, the findings of this study suggest that
the biological potential of dECM interface functionalization
can be increased by targeted selection and combination of
bioactive motifs. Since bioactive sequences within the dECM–
synthetic peptide platform are easily interchangeable and
combinable, further control of host cell proliferation, function,
and differentiation—beyond simple cell attachment—seems
feasible. Thus, the presented strategy could pave the way to a
new generation of multifunctional dECM scaffolds for re-
generative medicine, with particular implications regarding
the functional recellularization of engineered vascular grafts
and heart valves, possibly leading the way toward enhanced
endothelialization strategies.
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